Welcome to our dedicated page for SRX GLOBAL news (Ticker: SRXH), a resource for investors and traders seeking the latest updates and insights on SRX GLOBAL stock.
SRx Health Solutions, Inc. (NYSE American: SRXH) issues frequent press releases and SEC-referenced announcements that document its transition toward a digital-asset treasury operating model and its planned acquisition of EMJ Crypto Technologies Inc. (EMJX). The news flow provides insight into how the company is reshaping its strategy around a Gen2 digital-asset treasury platform that uses quantitative models, artificial intelligence and systematic risk controls.
Recent news items describe the definitive agreement to acquire EMJX, stockholder approval for a future name change to EMJX, Inc. and a planned ticker change to EMJX upon closing of the transaction. Company announcements also cover the deployment of an initial allocation of capital into digital assets such as Bitcoin and Ethereum, which the company characterizes as part of a measured, model-driven treasury management approach rather than short-term speculation.
Other SRXH news highlights enhancements to the EMJX platform, including integration of OpenAI large language models for research and risk decision support and the use of prediction-market probability data to strengthen its internal risk-intelligence framework. Governance and capital-markets updates appear regularly, such as the appointment of new directors with experience in cannabis, capital markets and cryptocurrency treasury strategies, amendments to the company’s charter to increase authorized shares, and private placements of preferred stock and warrants.
SRXH news releases also address NYSE American listing matters, including notifications of stockholders’ equity deficiencies and acceptance of the company’s plan to regain compliance with continued listing standards. For investors tracking SRXH, the news feed offers a consolidated view of transaction milestones, treasury activities, platform development and regulatory communications. Monitoring this page helps readers follow how the company’s proposed combination with EMJX progresses and how its digital-asset treasury strategy evolves over time.
SRX Global (NYSE American: SRXH) announced that NYSE Regulation has notified the company it is back in full compliance with all NYSE American continued listing standards in Part 10 of the Company Guide. The prior deficiencies under Section 1003(a)(i) and (ii) have been resolved, so the “.BC” compliance indicator will be removed and SRX Global will no longer appear on the NYSE American noncompliant issuers list.
SRX Global (NYSE American: SRXH) reported that its EMJX crypto‑treasury strategy generated a paper‑traded, time‑weighted total return of +24.8% from February 11 to July 10, 2026, versus Bitcoin at -4.2%, a spread of roughly 29 points over 149 days.
According to SRX Global, EMJX shifted its market‑regime signal for Bitcoin from “Stress” to “Mixed” and outperformed four crypto‑treasury comparables over 30 days, 60 days, and since inception. The multi‑asset model, now acquired by SRX Global, will be traded with real capital on a fully auditable basis, and the company is exploring additional investor‑accessible product formats. Management will discuss the regime shift, track record, and next steps in a live investor fireside chat on July 14, 2026, at 10:30 a.m. ET.
SRX Global (NYSE American: SRXH) will host a virtual fireside chat on July 14, 2026, at 10:30 a.m. ET, featuring CEO Kent Cunningham and Eric Jackson, to discuss recent developments including the completed EMJX acquisition and strategic outlook.
The company reports over $55 million in cash and short-term investments, no debt, and an estimated net asset value of about $3.07 per share. SRX Global announced a share repurchase program for up to 10 million common shares and a cash dividend of approximately $1 million in aggregate, funded from its SpaceX investment and hedging strategy. Management highlights recent capital deployment into several high-conviction investments and outlines an AI-enabled, three-pillar investment framework and four capital allocation priorities focused on balance sheet strength, fixed income, Halo, and strategic deals.
SRX Global (NYSE American: SRXH) authorized a stock repurchase program allowing buybacks of up to 10 million shares, or up to 50% of shares outstanding.
The Board allocated up to $20 million for repurchases through July 9, 2027, funded from the company’s cash on hand, with no obligation to repurchase any specific amount.
SRX Global (NYSE American: SRXH) reported a preliminary estimated net asset value of about $60 million, or $3.07 per share, as of June 30, 2026. The company held roughly $40 million in cash, over $15 million in short-term investments, and had no debt.
Following its EMJX acquisition and a 1-for-60 reverse stock split completed July 6, 2026, SRX Global had about 19.5 million shares outstanding. Management highlights a capital allocation framework focused on liquidity, treasury optimization, investing in Halo, and strategic investments and M&A.
SRX Global (NYSE American: SRXH) declared a one-time cash dividend of $0.05 per share, totaling about $1 million. Shareholders of record on July 22, 2026 will receive payment on or about August 3, 2026, funded by profits from its SpaceX investment and hedging strategies.
SRX Global (NYSE American: SRXH) announced a strategic investment in Greenland Mines, a critical and precious minerals development company.
Greenland Mines is advancing a portfolio of strategic mineral assets in Greenland, aligning with SRX Global’s AI-enabled platform focused on returns from high-conviction operating companies and assets.
SRX Global (NYSE American: SRXH) will implement a 60-to-1 share consolidation of its issued and outstanding common stock, effective July 6, 2026. Every 60 existing shares will automatically convert into one share on the Effective Date.
The stock will continue trading on NYSE American under the symbol SRXH and will trade on a consolidated basis with a new CUSIP from market open on July 6, 2026. No fractional shares will be issued; eligible holders will receive one whole share instead.
SRX Global (NYSE American: SRXH) announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company developing medical countermeasures against synthetic drugs like fentanyl.
ARMR’s lead candidate ARMR-100, in a Phase 1/2 trial, has generated an anti-fentanyl immune response in humans with favorable safety and aims to provide 6–12 months of protection, with the next trial phase planned for late 2026.
SRX Global (NYSE American: SRXH), formerly SRx Health Solutions, closed its acquisition of EMJ Crypto Technologies (EMJX) and launched an AI-driven capital allocation platform focused on high-conviction operating companies and assets.
EMJX’s Gen2 digital-asset treasury and Halo brands now operate under SRX Global, which has already invested in Astro Capital, Opendoor Technologies, Uber Technologies and Optimi Health.